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Abstract
Background: Natural compounds have been demonstrated to lower breast cancer risk and sensitize tumor cells to
anticancer therapies. Recently, we demonstrated that vernodalin (the active constituent of the medicinal herb
Centratherum anthelminticum seeds) induces apoptosis in breast cancer cell-lines. The aim of this work was to gain
an insight into the underlying anticancer mechanism of vernodalin using in vitro and in vivo model.
Methods: Vernodalin was isolated through the bioassay guided fractionation from the seeds. The protein
expression of p-Akt, PI3K, FOXO3a, Bim, p27kip1, cyclinD1, and cyclinE was examined by the Western blot analysis.
Immunoprecipitation assays were performed to analyse Akt kinase activity. Small interfering RNA (siRNA) was used
to study the role of FOXO3a upregulation and their targets during vernodalin treatment. Immunofluorescence,
subcellular localisation of FOXO3a by Western blot was performed to analyse FOXO3a localisation in nucleus of breast
cancer cells. Immunohistochemical analysis of PCNA, Ki67, p27kip1, FOXO3a and p-FOXO3a in the LA7-induced
mammary gland tumor model was performed.
Results: Our results showed that vernodalin regulates cancer cell apoptosis through activation of FOXO transcription
factors and its downstream targets (Bim, p27Kip1, p21Waf1/cip1, cyclin D1, cyclin E) as examined by Western blots.
Furthermore, we showed that FOXO3a/PI3K-Akt played a significant role in vernodalin induced apoptosis in breast
cancer cells. Immunoprecipitation assays showed Akt kinase activity was downregulated. Immunofluorescence,
subcellular fractionation and Western blot showed FOXO3a accumulation in the nucleus of breast cancer cells after
vernodalin treatment. Silencing of FOXO3a protected breast cancer cells against vernodalin induced apoptosis. The
anti-tumor action of vernodalin was further confirmed by examining cell proliferative markers, PCNA and Ki67 in the
LA7-induced mammary gland tumor model. We also corroborated our findings in vivo by showing upregulation of
p27Kip1, FOXO3a and decrease in the p-FOXO3a level in vernodalin-treated breast tumor tissue.
Conclusions: Our results suggest that PI3K-Akt/FOXOa pathway is a critical mediator of vernodalin-induced cytotoxicity
and this compound could be further developed as a potential chemopreventive or chemotherapeutic agent for breast
cancer therapy.
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Background
Breast cancer is the third leading cause of cancer deaths
and highest among women aged between 20 and 59 years
based on a cancer statistics in 2013 [1]. It is still the
leading cause of morbidity and mortality of women
worldwide; with 23 % (1.38 million) of new cancer cases
and 14 % (458,400) of the total cancer deaths [2]. Breast
cancer development and metastasis is a multistep
process, often caused by dysfunction of several regula-
tory features those keep cells in check [3]. Continents
such as North America, Western Europe and Australia
have been reported to have the highest incidence rates.
Nevertheless, it is increasing in all parts of the globe, es-
pecially in the developing countries. Steroid hormones,
particularly estrogen, contribute to the development and
progression of mammary gland neoplasia. Majority of
breast cancer is sporadic and the risk factors are mostly
linked to estrogen exposure and age [4]. The outcome of
breast cancer treatment during the past several years has
significant improvement, primarily due to early diagnosis
and chemotherapies. However, there is a relative lack of ef-
fective therapies for advanced-stage metastatic disease [5].
Most of the chemo-therapeutic drugs in market for
treating breast cancer cause harmful effects such as se-
vere nausea, vomiting, fatigue and hair loss. Hence, there
is an urgent need to develop alternative therapeutic
drugs with negligible side effects. One such alternative
could be the use of plant based chemo-therapeutic
drugs. Natural products, including phytoconstituents
and dietary agents have already been shown to suppress
the growth of breast tumor cells through modulation of
cell proliferation, cellular differentiation, apoptosis,
angiogenesis as well as several signal transduction path-
ways [6, 7]. Certain natural products are used in cancer
chemo-prevention to inhibit or revert carcinogenesis
and to suppress cancer malignancy [8]. The efficacy of
several dietary supplements and natural products in
breast cancer has been tested by clinical intervention tri-
als that support these potential utility of these agents in
the breast cancer prevention, treatment, and manage-
ment regimens in the future [9]. In addition, epidemio-
logical data suggest that consumption of plant foods or
natural products (47.2 %) and botanical supplements
(47.5 %) that contain high levels of antioxidants can slow
down or prevent the appearance of cancer [10, 11].
ForkheadboxO (FOXO) proteins, a subgroup of the
forkhead transcription factors, play an important role in
tumor suppression mainly by upregulating target genes
involved in cell cycle arrest and apoptosis [12]. In mam-
mals, this family of proteins consists of four members-
FOXO1, FOXO3, FOXO4 and FOXO6, and accumulated
evidence shows that FOXO3a regulates a wide range of
biological processes, including proliferation, apoptosis,
protection against oxidative stress, and metabolism [13].
In particular one of the FOXO members, FOXO3a is
under-expressed in many breast cancer patients [14].
Low levels of FOXO3 have been reported to confer
chemotherapy resistance in human cancers, being sig-
nificantly associated with poor prognosis in cancer pa-
tients [15, 16]. FOXO3a regulation and activity depends
mainly on the subcellular localisation, which can be
achieved via post-translational modifications including
phosphorylation, acetylation and ubiquitination [17].
Several studies indicate that the FOXO family is a key
downstream target of PI3K-Akt pathway in development
and longevity [18, 19]. Akt controls transcription of
FOXO3a target genes, through modulation of FOXO3a
activity by phosphorylating three conserved threonine/
serine residues (Thr-32, Ser-253, and Ser-315), leading
to the release of FOXO3a from DNA and translocation
to the cytoplasm [20, 21]. Reports suggest that up regu-
lation of FOXO3a proteins can promote apoptosis
through upregulation of the pro-apoptotic Bcl-2 family
member (Bim) and consequent increase in the cell cycle
protein levels of p27kip1. In contrast a CDK inhibitor,
(CKI) is capable of associating with cyclin-CDK com-
plexes and inhibits the apoptosis [22–24]. Therefore,
FOXO3a has been proposed as an important factor in-
fluencing the efficacy of a variety of chemotherapeutic
drugs. In fact, the restoration of FOXO3a expression has
been exploited for some mechanism-based anticancer
therapies [25, 26].
Cells replicate their genome and divide by the cell cycle
process. During this process, the cell cycle control is a cyc-
lically operating biochemical device consisted of numer-
ous interacting proteins, which induce and organize
proper progression, including cyclins, cyclin-dependent
kinases (CDK) and their inhibitors (CDKI) [27, 28]. Dys-
regulation of these regulators could give rise to cell growth
uncontrollably. PI3K/Akt signaling pathway is a vital
transduction pathway in regulating cell cycle and apop-
tosis. Different types of cancer, including human breast
cancer and lung cancer, reportedly activate this pathway
[29]. Recent studies have shown that some anti-cancer
drugs could down-regulate Akt to induce G1/S arrest
[30, 31]. Overactive PI3K/Akt pathway decreases apop-
tosis and tumor cell cycle arrest, which leads to growth or
proliferation of cancer. Akt phosphorylates GSK3β and
blocks its kinase activity, thereby allowing cyclin D1 to ac-
cumulate which could inhibit cells into S period from G1
phase. Akt can also negatively influence the expression of
cell cycle inhibitors such as KIP1 (also known as p27) and
WAF1 (also known as CIP1 or p21) [32].
Centratherum anthelminticum (L.) Kuntze, (plant
name has been confirmed with www.theplantlist.org)
generally known as kalajiri, somraj, black cumin or bitter
cumin, is a member of Asteraceae family. The seeds of
C. anthelminticum have been reported to have various
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pharmacological properties, such as anti-viral, anti-filarial,
anti-microbial, anti-fungal and anti-diabetic activities
[33–35]. We recently reported that the chloroform frac-
tion of C. anthelminticum seeds exhibited anti-oxidant
property by inhibiting tumor necrosis factor-α, and inhi-
biting breast cancer cells growth by interrupting the acti-
vation of nuclear factor-kappa B [36]. Our earlier report
demonstrated that vernodalin (the active compound iso-
lated through bioassay guided fractionation) can induce
apoptosis in human breast cancer cells via caspase path-
way [37]. Vernodalin (colourless oil) is a cytotoxic sesqui-
terpene lactone having two active α, β-unsaturated enoate
moieties (one on the lactone ring and the other on the
side chain). However, the molecular aspect of vernodalin
and its in vivo anti-tumor efficacy have not been studied.
This present study seek to investigate the cellular mecha-
nisms underlying the cytotoxicity effect of vernodalin in
human breast cancer cell lines and rat LA7 induced mam-
mary gland tumor model. Our results suggest that
FOXO3a is a key mediator of vernodalin induced cell
cycle arrest and apoptosis in breast cancer cells.
Methods
Plant material
The seeds of C. anthelminticum were procured from
the medicinal plant cultivation zone of Amritum Bio-
Botanica Herbs Research Laboratory Pvt. Ltd, Betul
Madhya Pradesh India. Voucher specimen (CA-9) was
deposited (9th August 2008) in the Department of
Pharmacology, University Malaya.
Extraction and isolation
The powdered seeds of C. anthelminticum (150 g) were ex-
tracted successively with chloroform (CHCl3) (3X250ml)
(Merck, Darmstadt, Germany) in a Soxhlet apparatus for
24 h. The extracts were collected, filtered and concentrated
to dryness under reduced pressure in a rotary evaporator
(<40 °C) under vacuum to yield 8.53 g. Then the dried
samples were fractionated into six fractions using High
Performance Liquid Chromatography (HPLC) as described
previously [37]. The chemical structure of vernodalin was
shown in the Additional file 1: Figure S1. The fraction con-
taining vernodalin were further subjected to HPLC isola-
tion until >90 % pure. The purified compound, vernodalin
was confirmed through spectral analysis as done in our
previous publication [37].
Cell culture
The human breast cancer cell lines, (MCF-7; MDA-MB
231) and rat mammary tumor cell line (LA7) were pur-
chased from the American Type Culture Collection
(ATCC, Manassas, VA, USA). Cells were cultured in
Dulbecco’s Modified Eagle Medium (Gibco BRL, Carlsbad,
CA, USA) supplemented with 10 % heat-inactivated fetal
bovine serum, 2 mM glutamine, 1 % penicillin and
streptomycin. LA7 cells were maintained in Dulbecco’s
Modified Eagle’s Medium supplemented with 5 % fetal bo-
vine serum, 1 % penicillin and streptomycin, 4.5 g/L glu-
cose, 0.005 mg/mL insulin, and 20 mM HEPES in
humidified environment with 5 % CO2 at 37 °C. For ex-
perimental purposes, cells in exponential growth phase
(approximately 70-80 % confluency) were used.
Immunofluorescence analysis of FOXO3
1X104 cells per well were seeded onto 96-well plate.
Cells were treated with vernodalin or DMSO (negative
control) and Doxorubicin (Purchased from Pfizer, USA)
at indicated concentrations for 24 h. The vernodalin
concentration and time was fixed based upon our previ-
ous publication [37]. Cells were fixed with 4 % formalde-
hyde for 15 min. Fixed cells were permeabilized with
0.1 % Triton X-100 in phosphate buffer saline (PBS).
Samples were blocked with 3 % bovine serum albumin
and incubated with FOXO3a primary rabbit antibody
(Cell Signaling Technology, Danvers, MA) for 1 h. Samples
were washed three times with wash buffer I (1 X PBS) be-
fore addition of goat anti rabbit secondary antibodies con-
jugated with DyLight™ 488 (Thermo Scientific). Cells were
rinsed three times with wash buffer II (1 X PBS with 1 %
Tween-20). Nucleus was stained with Hoechst 33258.
Stained cells were visualized and images were captured
using Cellomics ArrayScan HCS reader (Thermo Scientific,
USA). Cell health profiling bioapplication module was used
to quantify the fluorescence intensities of each dye.
Protein extraction
Cells treated with or without vernodalin for 24 h were col-
lected and lysed in cell lysis buffer (1 % NP-40, 0.5 % so-
dium deoxycholate, 0.1 % SDS) supplemented with freshly
added 10 mM β-glycerophosphate, 1 mM sodium ortho-
vanadate, 10 mM NaF, 1 mM phenylmethylsulfonyl fluor-
ide and Protease Inhibitor Cocktail (Santa Cruz, CA) for
30 min on ice. Then lysates were centrifuged at 12,000 × g
for 30 min at 4 °C. The concentration of total protein was
determined by Bradford assay (Bio-Rad, Hercules, CA).
The protein extracts were stored at -80 °C until further
processing.
Westernblot analysis
The extracts are heated in a boiling water bath for 5 min
and equal amounts of protein (40 μg) were separated by
10 % polyacrylamide gel. Proteins were then transferred
to microporous polyvinylidene difluoride (PVDF) mem-
brane (Milipore). Membranes were incubated in 5 %
BSA (Sigma) blocking buffer for 1 h at room
temperature. Incubations with primary antibody were
carried out overnight at 4 °C. Immunoblotting was per-
formed with the following antibodies: anti-FOXO3a,
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anti-p-FOXO3a (Ser-253), anti-p21Cip1/waf1, anti-
p27Kip1, anti-Bim, anti-cyclinD1, anti-cyclinE, anti-Akt
(total), anti-p-Akt (Thr-308), anti-p-PI3K, anti-total-
PI3K, anti-GAPDH, anti-LaminB1 (1:1000) (Cell Signal-
ing Technology, Danvers, MA) and mouse anti-β-actin
(1:10000) (Sigma) antibodies overnight at 4 °C. The next
day, the membranes were washed three times for 10 min
in TBS-T and incubated with the corresponding horserad-
ish peroxidase-conjugated secondary antibody for 1 h. To
remove excess antibodies, membranes were washed 4
times before HRP activities were detected using ECL Plus
Chemiluminescence Reagent (Amersham, Chalfont, UK)
according to the protocol supplied with the kit. Fi-
nally the quantification was done by ImageJ software
(NIH, Bethesda, MD).
Akt kinase activity
After appropriate treatments, Akt kinase assay was per-
formed using a non-radioactive Akt kinase assay kit (Cell
Signaling Technology) following the manufacturer’s in-
structions. Briefly, Akt was immunoprecipitated from
100 μg cell lysate overnight using an immobilized Akt
antibody. The beads were then pelleted and washed
twice in 500 μL of cell lysis buffer and twice in 500 μL
of kinase buffer. Pellets were resuspended in 25 μL of
kinase buffer containing 0.5 mL of 10 mM ATP, 1 mg
Glycogen synthase kinase-3 (GSK-3) fusion protein for
30 min at 30 °C. Kinase reaction was terminated by add-
ing sample buffer containing β-mercapatoethanol. Fi-
nally, the activity of Akt kinase in each sample was
determined according to GSK-3α/β phosphorylation by
Western blot.
Preparation of cytosol/nuclear extract
At 24 h after treatment, the MCF-7 and MDA- MB 231
cells were harvested and washed 3 times with cold
phosphate-buffered saline (PBS). The cytoplasmic and
nuclear protein fractions were extracted using NE-PER
nuclear/cytoplasmic extraction reagent (Cell Signalling
Technology). In brief 5 × 106 cells is pelleted by centrifu-
gation at 500 × g for 2-3 min. The cell pellet were
treated with ice-cold 500 μl of CER I (cytoplasmic ex-
traction reagent 1) then vortex the tube vigorously on
the highest setting for 15 s to fully suspend the cell pel-
let. Incubate the tube on ice for 10 min then add ice-
cold 27.5 μl of CER II to the tube then vortex the tube
for 5 s on the highest setting. Incubate tube on ice for
1 min; centrifuge the tube for 5 min at maximum speed
in a microcentrifuge (~16,000 × g). Immediately transfer
the supernatant (cytoplasmic extract) to a clean pre-
chilled tube the insoluble (pellet) fraction which contains
nuclei treated with ice-cold 250 μl NER (nuclear extrac-
tion reagent) keep the sample on ice and continue vor-
texing for 15 s every 10 min, for a total of 40 min then
centrifuged at maximum speed (~16,000 × g) in a micro-
centrifuge for 10 min. Immediately transfer the super-
natant (nuclear extract) fraction to a clean pre-chilled
tube. Store extracts at -80 °C until use. Cytoplasmic and
nuclear protein extracts were used for Western blot
analysis.
Gene silencing with small interfering RNAs (FOXO3a)
MCF-7/MDA-MB231 cells were cultured in six-well
plates until 60 % confluent and were transfected with l
μg of SiRNA duplex and scrambled oligonucleotides
using SiRNA transfection reagent (Sigma Aldrich sc-
37887) according to the manufacturer’s instructions.
48 h after transfection, cells were treated with vernodalin
or DMSO vehicle for 24 h. Then the cells were collected
for Western blot analysis.
Cell cycle analysis
Cell cycle analysis was performed using propidium iod-
ide staining as described previously with slight modifica-
tions [37]. Briefly, after silencing with FOXO3a cells
were washed in PBS and fixed in 90 % ethanol. Fixed
cells were then washed twice in PBS and stained in
50 μM propidium iodide containing 5 μg/ml DNase-free
RNase for 1 h, then analyzed by flow cytometry using a
FACS Canto II flow cytometer (BD Biosciences, USA).
Experimental animals and diet
The animal protocol was approved by the Institutional
Animal Use and Care Committee of the University of
Malaya (2014-05-07/PHAR/R/CYL). Pathogen-free female
Sprague-Dawley rats (6 weeks old) were obtained from
the Animal House, Faculty of Medicine, University of
Malaya, Kuala Lumpur. The animals were acclimatized to
standard laboratory conditions including a controlled en-
vironment at 24 ± 1 °C and 50 ± 10 % relative humidity
with the alternating 12:12-h dark–light cycle for 1 week
before the beginning of the study and provided with
standard food pellets and tap water ad libitum.
Cell preparation and mammary tumor induction
When the cells (LA7) were 90 % confluent, the medium
was removed and the cells washed with PBS to remove
dead and undetached cells. Low amount of trypsin-
EDTA was added to detach cells. Cells were obtained
immediately by centrifugation at 100 g for 10 min at 4 °C,
washed twice with PBS and dispersed. For viability detec-
tion, the cells were stained with trypan blue and counted
using a hemocytometer. Cells were eventually suspended
in 300 μL of PBS. All harvested cells were used within 1 h
of preparation. After one week acclimation period, rats
were anesthetized using an intraperitoneal (i.p.) injection
with a mixture of ketamine-HCl (150 mg/kg body weight)
and xylazine (10 mg/kg body weight). The LA7 cells
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(300 μL containing 5x106 cells) were inoculated subcuta-
neously into the mammary fat pad (left flank) of rats using
a tuberculin syringe and 21G needle to initiate tumor
growth. A total of twenty five female SD rats have been
used in this study. The animals were divided into five
groups (n = 5), where the Group (I) animals were kept as
the normal control group (NC) and received i.p. injection
of saline (300 μl) and served as a control. Group (II)
animals were classified as LA7-induced tumor control
group (TC). Groups (III) represent the low dose treat-
ment of vernodalin in tumor bearing animals (TT+
1 mg/kg-Vernodalin), Groups (IV) represent the high
dose treatment of vernodalin in tumor bearing ani-
mals (TT+ 10 mg/kg-Vernodalin), and Group (V)
represent the Tamoxifen treatment in tumor bearing
animals (TT+ 1 mg/kg Tamoxifen). For Group III to
V the Vernodalin and Tamoxifen (from Sigma Al-
drich, USA) were dissolved in saline separately and
the treatment was performed by intraperitoneal (i.p.)
injection three times/week after the appearance of
tumor (approximate size is 2 cm in 2 weeks) for an-
other three weeks. The body weight of each rat was
recorded weekly. At the end of the experimental
period (After five weeks), rats were fasted overnight
and the body weight of each rat was monitored.
Then, the rats were anaesthetized and sacrificed by
decapitation. Mammary tissue samples were obtained
washed twice with ice-cold 0.1 M phosphate buffered
saline (PBS), weighed and fixed in 10 % neutral-
buffered formalin for immunohistochemical analyses.
Tumor growth and measurement
The latency period and tumor incidence was determined
as tumor growth landmarks [38]. All animals were moni-
tored for mammary tumor development. Tumor diame-
ters and animal weight were measured every week. The
tumor mass was measured horizontally and vertically
using a digital caliper. Volume of tumor (V) was calcu-
lated by the formula determined by Carlsson: V = (ab2)/2,
where ‘a’ and ‘b’ is the longest and shortest diameters of
the tumor, respectively [39].
Histopathological examination
Kidney and liver tissues were fixed in 10 % buffered for-
malin, embedded in paraffin using a conventional auto-
mated system. The blocks were cut to obtain 5 mm
thick sections and stained with hemotoxylin–eosin. Ser-
ial paraffin sections of each tissue image were captured
by light microscopy (Nikon XDS-1B).
Immunohistochemical analysis
Paraffin embedded tissue sections of 5 μm thickness
were rehydrated first in xylene and then in graded etha-
nol solutions. Then, the slides were incubated with the
HistoVT (10x, pH 7.0) (Nacali Tesque, Tokyo, Japan)
antigen retrieval solution for 20 min in 90 °C followed
by cooling in room temperature. Next, the slides were
blocked with 5 % BSA in Tris-buffered saline-Tween 20
(TBS-T) for 2 h before the sections were immunostained
with primary antibodies of PCNA, Ki67, FOXO3a, p-
FOXO3a and p27Kip1 (Cell Signaling Technology, USA)
diluted 1:100 with 5 % BSA in TBS-T and incubated
overnight at 4 °C. After washing the slides thrice with
TBS-T, the sections were incubated with respective sec-
ondary antibodies with 5 % BSA in TBS-T and incubated
for 2 h at room temperature. Sections were then washed
with TBST and incubated for 5-10 min in a Peroxidase
stain DAB kit as per the instructions provided by the
manufacturer (Dako, Glostrup, Denmark). Counter stain-
ing was performed using hematoxylin (Cell Path, UK), and
the slides were photographed in light microscope (BX51,
Olympus, Japan).
Statistical analysis
Statistical analyses were processed according to conven-
tional procedures using the Statistical Program of Social
Sciences (SPSS) software for Windows, Version 12.0
(Post-hoc, Tukey’s test). A P value <0.05 was considered
statistically significant.
Results
Effect of vernodalin treatment on FOXO3 and its
downstream target molecules
Several studies showed that phytochemicals such as ge-
nistein exert anti-cancer effect via activation of FOXO3a
signalling [40, 41]. Therefore, in this study we embarked
to evaluate whether vernodalin (a cytotoxic compound
isolated from Centratherum anthelminticum seeds)
could affect FOXO3a expression in human breast cancer
cell-lines (MCF-7 and MDA-MB231). Our results
showed that vernodalin dose dependently (6.25, 9.5 and
12 μg/ml) induced higher expression of FOXO3a in both
MCF-7 and MDA-MB231 cells. In addition immuno-
blotting analysis showed a reduction of the phosphory-
lated forms of FOXO3a at the critical phosphorylation
sites (Ser253) after vernodalin treatment (6.25, 9.5 and
12 μg/ml) as compared with untreated control cells
(Fig. 1a and b). The cell cycle progression is regulated by
cyclin/cyclin-dependent kinase (CDK) complexes, as the
uncontrolled expressions of cyclins and/or CDKs may
lead to cell cycle dysregulation and tumorigenesis.
FOXO3a controls cell cycle progression by regulating
the downstream expression level of cell cycle inhibitor
p27Kip1 and p21 (Cip1/waf1). Results showed that
p27Kip1 and p21Cip1/waf1 were up-regulated, whereas
the levels of cyclin D1 and cyclin E were decreased in re-
sponse to vernodalin treatment (Fig. 2a and b). Similarly,
the pro-apoptotic protein Bim, another downstream
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target of FOXO3a was increased in both breast cancer-
lines cells at 24 h after vernodalin treatment (6.25, 9.5
and 12 μg/ml) as compared with untreated control cells
Fig. 1a and b.
FOXO3a subcellular localization is affected by vernodalin
treatment
Previously, we showed that FOXO3a is upregulated in ver-
nodalin treated breast cancer cells. Next, we seek to inves-
tigate if vernodalin treatment could relocate FOXO3a
protein to the nucleus in order to exert its function. We
treated MCF-7 and MDA-MB231 cells with vernodalin
for 24 h and the intracellular localization of FOXO3a was
analysed by immunofluorescent staining. As shown in
Additional file 2: Figure S2 and Additional file 3: Figure
S3, FOXO3a resided in the cytoplasm, with negligible nu-
clear staining in control untreated cells. Interestingly, ver-
nodalin treatment induced a change in the subcellular
localization of FOXO3a, with a significant proportion of
the protein being translocated to the nucleus after 24 h
treatment, comparable to standard drug Doxorubicin
(Additional file 2: Figure S2 and Additional file 3: Figure
S3). To confirm this, we performed nuclear/cytoplasmic
fractionation of breast cancer cells treated with vernoda-
lin. Western blot results showed higher expression of
FOXO3a in the nucleus compared with the cytoplasmic
fractionation after vernodalin treatment in MCF-7 and
MDA-MB231 cells (Fig. 3). This correlates with nuclear
translocation of the FOXO3a transcription factor that
may contribute to FOXO3a activation and induction of
cell death during vernodalin treatment.
FOXO3a silencing by siRNA abrogates vernodalin-induced
cell death
In order to confirm the relevance of FOXO3a in verno-
dalin mediated apoptosis, we performed gene silencing
experiments by transfecting MCF-7 and MDA-MB231
cells with siRNA specific for FOXO3a. As shown in
Fig. 4a, vernodalin treated or control siRNA transfected
cells have higher FOXO3a protein level. In contrast,
FOXO3a silencing by siRNA abrogated vernodalin-
induced expression of FOXO3a protein as determined
Fig. 1 Effect of Vernodalin on modulation of FOXO3a and Bim. Expression of FOXO3a/p-FOXO3a (Ser253) and Bim in breast cancer cells of MCF-7
(a) and MDA-MB231 (b). Whole cell lysates were prepared from the breast cancer cell lines after the vernodalin treatment for 24 h. The expression
of FOXO3a, phosphorylated FOXO3a, and Bim were analysed by Western blots as described in “Materials and Methods”. β-actin was used as loading
control. The data are representative of three experiments. Respective blots were quantified using ImageJ software. Data’s are expressed as mean ± S.D.
All the treatment groups were compared with control. “*” denotes statistically significant at P < 0.05
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Fig. 2 (See legend on next page.)
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by Western blot. In addition, cell cycle analysis showed
that silencing of FOXO3a by siRNA can partially rescue
cells from vernodalin-mediated cell apoptosis. This is
evident from the decrease in the proportion of cells in
the sub-G1 phase in siFOXO3a-transfected breast cancer
cells when compared with the control siRNA-transfected
cells (Fig. 4b and c). To further show that FOXO3a has
an essential role in response to vernodalin treatment, we
transfected the MCF-7 and MDA-MB231carcinoma cells
with either a FOXO3a-specific siRNA or control siRNA
and studied the levels of cell cycle regulatory proteins
after vernodalin treatment. Western blots analysis showed
that the FOXO3a-specific siRNA, but not control siRNA,
inhibited the induction of p27Kip1, p21cip1/waf1, and in-
creased the cyclin D1 protein levels (Fig. 4d and e). These
results suggested that vernodalin targets FOXO3a to me-
diate apoptosis in breast cancer cells.
Vernodalin-induced activation of FOXO3a is dependent
on PI3K/Akt signaling pathway
In our study, we examined the role of vernodalin on
PI3K/Akt signaling in both breast cancer cell-lines. In
control cells, Akt and PI3K are predominantly acti-
vated, while vernodalin treatment markedly reduced
the phosphorylation of Akt and PI3K as compared
with control (Fig. 5a and b). This correlates with our
previous Western blot data, which showed vernodalin
treatment, lead to decrease level of p-FOXO3a. The
Akt kinase activity was further assessed by the phosphor-
ylation of GSK-3 protein through immunoprecipitation
and Western blots. Immunocomplex kinase assay of
Akt revealed that treatment with vernodalin for 24 h
significantly abolished Akt kinase activity in MCF-7
and MDA-MB231 cells (Additional file 4: Figure S4).
We have also checked whether any feedback regula-
tion during FOXO3a silencing and analysed the pro-
tein levels of Akt and p-Akt during vernodalin
treatment in control, FOXO3a specific siRNA and we
could not find the significant changes in regarding
with the feedback regulation (Additional file 5: Figure
S5). Taken together, these observations suggest the
importance of Akt signaling cascade in the activation
of transcription factor FOXO3a and the extent of cell
death caused by vernodalin in MCF-7 and MDA-
MB231 cells.
Tumor development, body weight, tumor size and
volume
During the experimental period, the rats tolerated the
subcutaneous administration of LA7 rat mammary
tumor cells and vernodalin treatment by intraperitoneal
injection. There were no clinical signs of toxicity related
death in experimental groups. Histology of the liver and
kidney tissues after vernodalin treatment (1 mg/kg and
10 mg/kg) was shown in the Additional file 6: Figure S6.
As hematoxylin–eosin (H–E) staining these organs did
not revealed histopathological abnormalities, degener-
ation, lesions or necrosis during the treatment. Liver
sections of control and vernodalin treated rats exhibiting
a concentric arrangement of the hepatocytes with sinus-
oidal cards around the central vein and portal tracts.
Kidney sections of control and vernodalin treated rats
showing normal renal tubules, corticomedullary junc-
tion, and glomeruli within the cortex region. The breast
tumors started to develop within 7-10 days after LA7
cells injection. The body weight, tumor volume and the
tumor percentage (%) of control and treated animals is
represented in Table 1. There was no significant body
weight decreases in the tumor bearing rats (Group II-V)
when it was compared with control rats (Group I).
(See figure on previous page.)
Fig. 2 Effect of Vernodalin on modulation of cell cycle proteins. a & b Shows the Western blots expression of p27kip1, p21cip1/waf1, cyclin D1
and cyclin E in breast cancer cells of MCF-7 and MDA-MB231. β-actin was used as loading control. The data are representative of three experiments.
Respective blots were quantified using ImageJ software. Data’s are expressed as mean ± S.D. All the treatment groups were compared with control. “*”
denotes statistically significant at P < 0.05
Fig. 3 FOXO3a cytoplasmic and nuclear protein expression in MCF-7
and MDA-MB231 cells after vernodalin treatment. MCF-7 and MDA-
MB231 cells were treated with vernodalin for the indicated time periods,
and the subcellular fractions were then isolated and immunoblotted for
FOXO3a. Lamin B1 and GAPDH were used as markers of the nucleus and
cytoplasm respectively. Vernodalin treatment caused the translocation of
FOXO3a from the cytoplasm to the nucleus. Results are representative of
three independent experiments
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Fig. 4 Effect of FOXO3a silencing during vernodalin treatment in MCF-7 and MDA-MB231 cells. a Cells were pre-treated with scrambled siRNA
or siFOXO3a for 48 h, followed by vernodalin (9.5 μg/ml) treatment for 24 h in MCF-7 and MDA-MB231 cells. All groups of cells were analysed
by using Western blots. b & c Cells were fixed in ethanol and stained with propidium iodide, and then the percentage of apoptotic cells was
determined by flow cytometry. Data are presented as means ± SD of three independent experiments (*P < 0.05). d & e Cells were pre-treated with
scrambled siRNA or siFOXO3a for 48 h, followed by vernodalin (9.5 μg/ml) treatment for 24 h in MCF-7 and MDA-MB231 cells. Protein lysates were
prepared at the times indicated and the levels of p27kip1, p21cip1/waf1 and cyclin D1 were analysed by using Western blots. Data are presented
as means ± SD of three independent experiments
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The tumor volume in untreated LA7 breast tumor
bearing rats was enlarged up to 2143 ± 363 mm3,
whereas a significant decrease in tumor volume
(1182 ± 352 mm3, 524 ± 261 mm3) was observed in
the treatment groups (low and high dose of vernoda-
lin), comparable to the standard drug Tamoxifen-
treated group 562 ± 145 mm3 (Table 1).
Vernodalin inhibited rat breast tumor growth in vivo by
targeting FOXO3a
To assess the proliferation rate of breast tumor cells, the
proliferation indexes were evaluated by Ki-67 and PCNA
staining. The untreated LA7 breast tumor bearing rats
(Group II) revealed intensive staining of PCNA and Ki-67
(Fig. 6), whereas, the vernodalin treated animals (Group
Fig. 5 Effect of vernodalin on modulation of PI3K/Akt signalling. MCF-7 cells and MDA-MB231 were left untreated or treated with vernodalin at
indicated concentration for 24 h (a & b) Expression of Total Akt, p-Akt, Total PI3K and p-PI3K were analysed by immunoblot analysis. Respective
blots were quantified using Image J software (c & d). E & F shows the ratio between P-PI3K and total PI3K protein. All the treatment groups were
compared with control. “*” denotes statistically significant at P < 0.05. Results are shown as percentage values ± SD of three independent
experiments
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III and IV; low and high dose respectively) exhibited a
substantial decrease in the numbers and intensity of cell
proliferation markers such as Ki67 and PCNA, compar-
able to a standard drug, Tamoxifen (Group V). As we
showed that vernodalin could inhibit phosphorylation of
FOXO3a in vitro, next we examined the phosphorylation
status of FOXO3a and total FOXO3a protein in tumor
tissues by immunohistochemistry. Treatment of rats with
vernodalin inhibited the phosphorylation of FOXO3a and
increases the total FOXO3a protein levels as compared to
untreated control (Fig. 7). Since cell cycle inhibitor
p27Kip1 is one of the targets of the FOXO transcription
factor, we next examined the effect of vernodalin on the
expression of p27Kip1 (Fig. 7). Immunohistochemistry
Table 1 Treatment effect of vernodalin and TAM on animal body weight (g), tumor volume (mm3) and tumor reduction percentage
(%) in LA-7-induced breast cancer rats
Group Treatment groups Body weight (g) Tumor volume (mm3) Tumor reduction percentage (%)
I NC 247.3 ± 1.5 0 0 %
II TC 213.13 ± 1.32 2143 ± 363 0 %
III TT (1 mg/kg vernodalin) 219.14 ± 7.2 1182 ± 352* 44.84 %
IV TT (10 mg/kg vernodalin) 221.57 ± 5 524 ± 261* 75.6 %
V TT (1 mg/kg TAM) 224.88 ± 5.7 562 ± 145* 73.78 %
Each value represents mean ± S.D. of given number of animals (n = 5). “*” denotes statistically significant at p < 0.05 compared to control group
Fig. 6 Effect of vernodalin treatment on proliferation markers (Ki-67 and PCNA) in breast tumor tissue. Sprague dawley rats were implanted with
LA7 cells. Rats were treated with low and high dose of vernodalin (1 or 10 mg/kg) and the standard drug Tamoxifen (1 mg/kg). Tumor tissues
were collected in 10 % formalin and blocks were prepared in paraffin and immunohistochemistry of PCNA and Ki67 were performed as described
in “Materials and Methods”. Photomicrographs show representative pictures from five independent tumor samples. Bar =10 μm. Quantification of
Ki-67 and PCNA positive cells in tumor tissues was shown (*P < 0.05)
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Fig. 7 Effect of vernodalin on expression of cell cycle inhibitor p27/Kip1, p-FOXO3a and FOXO3a in breast tumor tissue. Sprague dawley rats were
implanted with LA7 cells. Rats were treated with low and high dose of vernodalin (1 or 10 mg/kg) and the standard drug Tamoxifen (1 mg/kg).
Tumor tissues were collected in 10 % formalin and blocks were prepared in paraffin and immunohistochemistry of p27kip1, p-FOXO3a and
FOXO3a were performed as described in “Materials and Methods”. Photomicrographs show representative pictures from five independent tumor
samples. Bar =10 μm. Quantification of p27/Kip1, p-FOXO3a and
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result reveals that p27Kip1 expression is higher in rats
treated with low and high dose vernodalin (Group III and
IV) compared with untreated LA7 tumor bearing animals
(Group II). These data suggest that vernodalin can cause
growth arrest in tumor cells in vivo by inducing the ex-
pression of FOXO3a and p27Kip1.
Discussion
Dysregulated proliferation is one of the main mecha-
nisms for breast tumorigenesis, which involves different
stages such as initiation, promotion and progression of
tumor growth, thereby increasing the tumor burden and
the increase the chances of metastasis. This dysregula-
tion mainly occurs due to disrupted G1/S phase cell
cycle transition during malignant neoplasm development
[42]. Recently, research on the therapeutic activities of
natural products in cancer therapy with diverse roles
and targets are gaining attention [43–45]. Our previous
studies revealed that vernodalin isolated from C. anthel-
minticum seeds possess anticancer property in breast
and skin cancer model [37, 46]. However, the precise
mechanism whereby vernodalin influences apoptosis in
breast cancer remains unclear. FOXO transcription fac-
tors play an important role in tumor suppression by up-
regulation of pro-apoptotic genes, such as Bim and
p27Kip1 in various tumors [47–50]. In this study, we
evaluated the expression of FOXO3a and other important
cell cycle molecules in response to vernodalin treatment.
Subsequently, we examined the effect of vernodalin on
PI3K/Akt pathway and provided evidences showing that
FOXO3a activation could inhibit breast cancer cell prolif-
eration and tumorigenesis.
Cell-cycle dysregulation is an attribute of tumor cells,
thus cell-cycle arrest has become the major focus of
anti-cancer effects. Anti-tumor agents can cause cell
cycle arrest in various phases by regulating the cell-cycle
machinery [51]. We previously reported that vernodalin
induced cell cycle arrest at G0/G1 stage in breast cancer
cells [37]. In the present study, we observed loss of cyc-
lin D1, cyclin E expression and upregulation of p21 and
p27 levels during vernodalin treatment. The p21 and
p27 belong to the Cip/Kip family negatively regulate the
cell cycle progression through inhibition of CDK-cyclin
complexes [52]. On the other hand, cyclin D1 and cyclin
E are major cell cycle regulatory proteins and mainly in-
volved in the G1/S phase transition in normal cells. Over
expression of these cyclin altered the cell cycle progres-
sion and closely associated with malignancy. The dysreg-
ulated cell proliferation plays an important role in
multistage oncogenesis, which could caused by over ex-
pression of cyclins D1, E, and CDK4 complexes [53, 54].
The G1/S-phase transition is tightly regulated by CDKIs
such as p21 and p27 via inactivation of G1 (CDK) com-
plexes [55, 56]. Taken together, our data reveal a novel
cell cycle regulating property of vernodalin via G1-phase
arrest.
Apoptotic cell death is a complex program mainly
controlled by the Bcl-2 family proteins. We previously
reported that the apoptosis induction in vernodalin-
treated MCF-7 and MDA-MB231 cells is associated with
upregulation of Bax (a Bcl-2 family member), cyto-
chrome c release and caspases activation [37]. However,
it was known that the presence of BH3-only molecules
like Bim is required for direct activation of Bax at the
mitochondria. In this study, we observed an increase in
the protein expression of Bim after vernodalin treatment
in breast cancer cells (Fig. 1a and b). Bim was also
shown to be a direct downstream target of FOXO3a
[57]. It is widely known for its pro-apoptotic functions
in mitochondria and it can induce apoptosis by interact-
ing with proteins such as Bcl-xL and Bcl-2 that shows
anti-apoptotic function [58]. PI3K/Akt pathway is a cell
survival pathway that is important for normal cell
growth and proliferation. Numerous researches in breast
cancer have shown that deregulation of this pathway is
implicated in tumorigenesis and hence this has become
an important target for breast cancer treatment. Notably,
this pathway regulates the development and progression
of human breast cancer by modulating the status of
anti-apoptotic proteins, by mediating cell cycle arrest
and inhibiting aerobic glycolysis via Akt which would
preferentially kill tumor cells via oxidative stress [56, 59].
As the amplification of PI3K/Akt signal transduction is
the main force that drives cellular growth, thus abrogation
of PI3K or Akt function might be crucial for cancer ther-
apy. Of note, phosphorylated Akt is an attractive molecu-
lar target because it contributes to the development of
breast cancer and confers resistance to conventional ther-
apies [60] In this study, we observed decreased expression
of p-Akt and p-PI3K after vernodalin treatment in both
breast cancer cell-lines (Fig. 5) and this was further con-
firmed by in vitro kinase assay of Akt showed diminished
phosphorylation of fusion protein GSK in vernodalin
treated breast cancer cells and reflects the inhibitory effect
of vernodalin on Akt kinase which clearly demonstrated
that nuclear localization of FOXO3a was dependent on
Akt signalling [61]. GSK3β is reported to regulate cell
cycle analysis and apoptosis, Akt prevents the apoptotic
activity of GSK3β by phosphorylation [62]. Our results
suggested that vernodalin reflects the decrease in the Akt
kinase activity as evaluated by the phosphorylation of
GSK-3β protein as shown in (Additional file 4: Figure S4).
FOXO3a is an important downstream effector of the
PI3K/Akt pathway. These proteins have emerged as
major regulators that control cellular activities, through
the orchestration of different patterns of gene expression
in response to diverse stimuli [63]. Activation of Akt
leads to phosphorylation of FOXO3a, resulting in its
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deactivation through nuclear export, while inhibition of
Akt leads to dephosphorylation, nuclear localization and
activation of FOXO3a [64]. The cytosolic retention of
FOXO3a prevents the transactivation of downstream
target genes such as Bim and p27Kip1. We hypothesized
that the inhibition of Akt phosphorylation by vernodalin
would lead to nuclear accumulation of FOXO3a and in-
creased transcription of downstream responsive genes.
Studies have shown that FOXO3a is dephosphorylated
and activated by LY294002 (a potent inhibitor of PI3K),
which correlates with upregulation of p27Kip1 [65]. It
has been previously demonstrated that FOXO3a path-
way can induce Bim expression and subsequently caus-
ing cell death in cancer models, such as MCF-7, mice
xenografts model of pancreas tumor and lymphoma cells
[66–68]. In agreement with the hypothesis, our study
provides clear evidence that vernodalin treatment re-
sulted in the activation (Fig. 1) and nuclear translocation
(Fig. 3, Additional file 2: Figure S2 & Additional file 3:
Figure S3) of FOXO3a in breast cancer cells via PI3K/
Akt inhibition (decrease phosphorylation status of PI3K/
Akt and increase translocation of FOXO3a to the nu-
cleus). Furthermore, silencing of the endogenous FOXO3a
expression by siRNA rescued the breast carcinoma cells
from undergoing proliferative arrest and apoptosis in re-
sponse to vernodalin treatment, suggesting that the induc-
tion of FOXO3a expression has a direct role in mediating
the effect of vernodalin. Transiently silenced FOXO3a also
reversed the down-regulation of p21Cip1 and p27Kip1 cell
cycle inhibitory proteins and increased cyclinD1 during
vernodalin treatment in MCF-7 and MDA-MB 231cells
(Fig. 4). These findings indicate that silencing of FOXO3a
and vernodalin treatment in breast cancer cells modulates
the expression of cyclinD1, p21Cip and p27Kip1 is
FOXO3a/PI3K/Akt dependent manner. These results are
consistent with previous published data showing that lapa-
tinib also targets FOXO3a in breast cancer cells to induce
apoptosis [69]
For in vivo study, we used rat mammary tumor cells
(LA7) to induce mammary tumors in the right flank of rats
to produce malignancy. Using this method, the mammary
gland tumor developed within 7-10 days at the site of in-
jection [70]. Current findings indicate that the applied low
(1 mg/kg) or high (10 mg/kg) vernodalin dosages did not
produce any toxicity sign in rats. Using these dosages, we
observed a significant decrease in tumor volume in treat-
ment groups, indicating vernodalin could suppress breast
tumor growth in vivo. The result was comparable to a
standard drug tamoxifen, which has been widely used for
the treatment of breast cancer [71]. The anti-proliferative
action of vernodalin was further confirmed using cell pro-
liferative markers, namely PCNA and Ki67. PCNA (cell
cycle related protein) is synthesized in early G1 to S-phase
function in the cell cycle progression; DNA replication and
repair [72]. Whereas Ki67 (nuclear protein) is required for
maintaining cell proliferation and commonly used to evalu-
ate the solid tumor cell proliferation [73]. In the current
study, we observed increased expression of PCNA and
Ki67 in breast tissue of control/untreated group. Concomi-
tantly, these proliferative markers expression was efficiently
decreased after vernodalin treatment (Fig. 6), indicating
the inhibition of mammary gland tumorigenesis. Moreover,
vernodalin induced the expression of FOXO3a protein and
their target genes p27Kip1 in breast tumor tissues and de-
crease the level of p-FOXO3a protein, consistent with our
in vitro studies (Fig. 7). These findings prove that ver-
nodalin can inhibit the cell proliferation and breast
carcinogenesis through G1/S phase cell cycle arrest. A
schematic representation of vernodalin mechanism is
shown in Fig. 8.
Fig. 8 Schematic representation of mechanisms underlying vernodalin-induced cytotoxicity in breast cancer cells. Vernodalin treatment inhibits
the activation of PI3K/Akt pathway, which enhances accumulation of nuclear FOXO3a in MCF-7 and MDA-MB231 cells. Nuclear FOXO3a promotes
the transcription and expression of Bim, which could activate Bax and causes cell death or apoptosis. On the other hand, FOXO3a upregulates
p21Cip1/waf1, p27Kip1, downregulates cyclin D1 and cyclin E leading to cell cycle arrest
Ananda Sadagopan et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:147 Page 14 of 17
Conclusion
It is obvious that vernodalin interferes with cellular pro-
cesses by targeting different intracellular molecules. Using
in vitro breast cancer cell-line model, we demonstrated that
the cytotoxicity of vernodalin is mediated through FOXO3a
activation. In addition, in vivo experiments reveal that
vernodalin inhibits rat breast tumor growth by targeting
FOXO3a and its downstream molecule, p27Kip1. Our re-
sults suggest that a combination of PI3K/Akt/FOXO signal-
ing pathway is responsible for the cytotoxicity of vernodalin
against breast cancer cells and this could also serve as a
new target gene for the therapeutic or preventive interven-
tion in breast cancer as well as other cancer typologies.
Additional files
Additional file 1: Figure S1. Chemical structure of Vernodalin.
(JPG 130 kb)
Additional file 2: Figure S2. Vernodalin treatment induces FOXO3a
nuclear translocation in MCF-7 cells. MCF-7 cells were treated with DMSO
(control) or indicated concentration of vernodalin for 24 h. Immunofluorescent
staining was then performed using the FOXO3a antibody (green) and stained
with Hoechst 33258 (blue). Images were acquired using cellomic HCS array
scan reader (objective 20X). Representative figures (control, 6.25, 9.5 μg/ml
of vernodalin and Doxorubicin 3 μg/ml) were shown. Bar chart shows
average fluorescence intensities of FOXO3a accumulation in the nucleus.
Data were mean ± SD of fluorescence intensity readings representative of
three independent experiments. (*P< 0.05). (JPG 536 kb)
Additional file 3: Figure S3. Vernodalin treatment induces FOXO3a
nuclear translocation in MDA-MB-231 cells. MDA-MB231 cells were treated
with DMSO (control) or indicated concentration of vernodalin for 24 h.
Immunofluorescent staining was then performed using the FOXO3a antibody
(green) and stained with Hoechst 33258 (blue). Images were acquired using
Cellomic HCS array scan reader (objective 20X). Representative figures (control,
6.25, 9.5 μg/ml of vernodalin and Doxorubicin 3 μg/ml) were shown. Bar
chart shows average fluorescence intensities of FOXO3a accumulation
in the nucleus. Data were mean ± SD of fluorescence intensity readings
representative of three independent experiments. (*P < 0.05). (JPG 573 kb)
Additional file 4: Figure S4. AKT kinase assay. Akt enzymatic activity
was evaluated by phosphorylation of a GSK-3 fusion protein after
immunoprecipitation of Akt using a nonradioactive Akt kinase kit as
described in the Materials and Methods section. The relative intensity of
the p-GSK3α/β band reflected the AKT kinase activity and Total-AKT was
immunoblotted as controls. GSK-3 phosphorylation bands were analysed
densitometrically. All the treatment groups were compared with control. “*”
denotes statistically significant at P < 0.05. Results are shown as percentage
values ± SD of three independent experiments. (JPG 318 kb)
Additional file 5: Figure S5. Effect of FOXO3a-specific siRNA on
expression of AKT and p-AKT in response to vernodalin treatment in
MCF-7 and MDA-MB231 cells. Cells were pre-treated with scrambled
siRNA or siFOXO3a for 48 h, followed by vernodalin (9.5 μg/ml) treatment
for 24 h in MCF-7 and MDA-MB231 cells. Protein lysates were prepared
at the times indicated and the levels of AKT and p-AKT were analysed
by using Western blots. Data are presented as means ± SD of three
independent experiments. (JPG 255 kb)
Additional file 6: Figure S6. Histopathological study of kidney and
liver tissues from control or vernodalin treated rats. A.control
(untreated). B. vernodalin 1 mg/kg- treated. C. vernodalin 10 mg/kg-
treated. (n = 5). Liver sections of control and vernodalin treated rats
showing normal architecture of hepatocytes with visible central vein
and normal arrangement of hepatocytes. Kidney sections of control
and vernodalin treated rats showing normal glomerular, tubular
sections. Representative micrographs of histologic sections were
shown at 20× magnification. (JPG 396 kb)
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